BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
On Friday, the FDA approved BridgeBio Pharma, Inc.’s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
Pharmaceuticals announced that the U.S. Food and Drug Administration or FDA, has accepted for review the Company’s supplemental ...
On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...